e - ISSN – 3117-4191
Print ISSN - 3117-4183

INTERNATIONAL JOURNAL OF PEDIATRIC NURSING

Journal homepage: www.mcmed.us/journal/ijpn



COMPREHENSIVE APPROACHES AND FUTURE DIRECTIONS IN PEDIATRIC ASTHMA CARE

Dr. Ganesan R*

Professor, Dept. of Pediatric Nursing, College of Nursing, Chengalpattu Govt. Medical College, Chengalpattu, Tamil Nadu, India.

Article Info

Received 05/02/2026
Revised 15/02/2026
Accepted 04/03/2026

Key word:
Children asthma, asthma control, non-drug medicine, personalized medicine.

ABSTRACT

Asthma in children is a common long-term respiratory disorder, which has to be managed in a complex way to be effectively managed. It is a chronic inflammatory disease accompanied by bronchoconstriction of airways and is associated with the need of a combination of non-pharmacological and pharmacological treatment. Pharmacological management the therapeutic intervention is comprised of reliever and controller drugs, aimed at symptom control, inflammation, and exacerbation prevention. Long-term asthma control is also supported by the use of non-pharmacological interventions, such as allergen avoidance, breathing exercises, and patient education. Healthcare providers, caregivers, and nurses have a very important role in further management of asthma with the use of personalized asthma action plans, frequency monitoring as well as education. Furthermore, school-based and community-based care plays an essential role in guaranteeing that asthmatic children are provided with the required care beyond the medical facilities. The treatment has been improved, but some challenges, such as medication adherence, controlling triggers, and differences in care access still exist. Going forward, the future trends in the treatment of asthma in children are on the following: personalized medicine, biologic treatment, and digital health, all to enhance the effectiveness of treatments and to reduce the impact of the disease. Further studies of the molecular pathways that drive the development of asthma and better coordination in the care provided in different environments will help to increase the quality of life and the management of asthma in children affected.

INTRODUCTION

One of the most prevalent chronic diseases in children is pediatric asthma, which has a significant effect on the quality of life of children and may have to be managed continuously during childhood and adolescence. It is a respiratory disorder that is characterized by chronic inflammation and intermittent airway blockage that usually leads to incidences of wheezing, coughing, dyspnea, and chest tightness. The pathophysiology of asthma in children is complicated by genetic predisposition and environmental influences like allergens, respiratory infections and air pollution that promote bronchoconstriction, airway hyperresponsiveness and inflammation [1–5]. The initial diagnosis and proper treatment are essential to limit the manifestation of asthma and avoid permanent damage to the lungs and poor health outcomes. The pharmacological management of asthma is the core of the asthma control with medications being divided into reliever and controller medications. The use of reliever medications (short-acting beta-agonists) during an acute exacerbation of COPD leads to relaxation of airway smooth muscles to relieve the symptoms, and the use of controller medications (inhaled corticosteroids and

Corresponding Author
Dr. Ganesan R

Email: abiganesh68@gmail.com

leukotrienes modifiers) helps to decrease airway inflammation and prevent acute exacerbation. The conventional model of treating asthma in children is the step-wise therapy method, which starts with light management of infrequent symptoms and goes up the ladder as often as there are more severe symptoms. This will be the best way to ensure that children are given the best therapy according to the level and the recurrence of the symptoms. Non-pharmacological management is also important in asthma management besides pharmacological management. Breathing exercises (e.g., diaphragmatic breathing) may be used to improve the functioning of lungs and decrease the symptoms by improving the airway opening and decreasing the rate of asthma attacks. Moreover, it is important to have environmental control measures to reduce contact with allergens, irritants and pollutants in long-term asthma management. The contribution of the nurses in the long-term care of the children with asthma is even more than providing medications and conducting examinations. Nurses also play the role of educators as they can educate patients and their families about the nature of asthma, its triggers, and asthma action plans. Each of these action plans is specific to the needs of each child and gives clear guidelines on how to handle asthma attacks and what to do when medical assistance is needed. Nurses also help in medication adherence follow-up, inhaler use assessments in kids, and determining the impact of the asthma management program. Another aspect of importance is school-based asthma care because children with asthma spend a major part of their time at school. Nurses collaborate with educators and school personnel to create tailored care plans so that children can have their medications and are assisted in asthma exacerbation. Engaging in community-based asthma care programs is also critical, which provides the outreach and support services to the families in the underserved communities, deliver the information on managing asthma, and refer the family to medical facilities. Although the current developments in asthma management have been achieved, a number of challenges have been encountered including medication compliance, environmental factors, and the complexity of asthma treatment among a wide range of people. The future approaches of pediatric asthma treatment include the development of individualized medicine, the development of new biologic therapy, and the expanded application of telemedicine in the process of asthma treatment. The objective in our further investigations of these new solutions is to offer holistic and personalized care that will ensure that asthmatic children can live healthy lives[6,7].

Pathophysiology of Asthma in Children

In children, asthma is a persistent airways inflammation disorder that leads to nonstop occurrence of wheezing, coughing, dyspnea or difficulty breathing, and chest tightness. Asthma pathophysiology comprises of multifactorial interactions between genetic predisposition and environmental determinants that combine with each other to cause airway inflammation, bronchoconstriction, and airway hyperresponsiveness. The onset of asthma usually occurs in the early childhood age and the symptoms usually manifest themselves before the age of 5 and it can continue into adolescence and adulthood[8–10]. The pathophysiology of asthma largely depends on the response of the immune system to the allergens, respiratory infections and irritants. Exposure to environmental inducers in children with a genetic predisposition to asthma like dust mites, moulds, pet dander, tobacco smoke and air pollution may activate T-helper 2 (Th2) lymphocytes. These cells secrete inflammatory cytokines that trigger cascade of immune reactions, which stimulates the invasion of eosinophils, mast cells and other immune cells into the airway tissues. This causes swelling of the airways, production of more mucus as well as inflammation of the airways, which causes the airways to be narrow and therefore restricts easy movement of air in and out of the lungs. Another typical manifestation of asthma is bronchoconstriction, whereby the smooth muscles that surround the airways contract in response to stimuli and further limit airflow. This narrowing of the bronchi is usually reversible, using bronchodilator drugs, including beta-agonists, which relax the smooth muscles and enhance airflow. The other significant facet of asthma pathophysiology is airway hyperresponsiveness, which is the exaggerated airways sensitivity to various stimuli that are known to induce asthma such as allergens, cold air, respiratory infections, and exercise. Such increased response may cause asthma exacerbations when the symptoms increase and need a more severe treatment. Besides these cellular and molecular mechanisms, the alteration of the structure in the long-term, referred to as airway remodeling, also leads to the chronicity of asthma. Long term changes in the airways structure include airway thickening of the basement membrane, smooth muscle mass increase and fibrosis, which is referred to as airway remodeling. Such alterations may result in sustained airflow restriction even without acute inflammation, and potentially result in the emergence of more severe asthma. Preventive measures of asthma change and management of asthma symptoms early in the disease are essential in changing the long-term outcomes of children. Besides, the interaction of asthma with other comorbid conditions, including allergic rhinitis, dermatitis, and obesity, contributes to the further complexity of the management of

asthma. The severity and the progression of asthma can also be affected by environmental factors, including being exposed to viral respiratory infections. Asthma in later life has been reported to have a higher chance of developing in the case of respiratory syncytial virus (RSV) infections in early childhood. It is important to comprehend the pathophysiology of asthma among children to develop specific treatment and management plans. Developments in immunotherapy, biologic drugs and individualized management are contributing to improved intrusion of asthma symptoms, decrease in inflammation and avoidance of permanent damage to the lungs and eventually enhances the quality of life in a child with asthma[11–13].

Bronchoconstriction

Bronchoconstriction is a basic aspect of asthma and other respiratory diseases which involves the tightening of the airways in the lungs, which occurs because of the contraction of the smooth muscle around the bronchi and bronchioles. The result of such physiological response is the limitation of airflow causing the typical symptoms of asthma (wheezing, coughing, chest tightness and shortness of breath). Bronchoconstriction is commonly caused by many environmental factors in children such as allergens (such as pollen, pet dander, or dust mites), respiratory infections, cold air, exercise, and exposure to irritants such as tobacco smoke or air pollution[14–16]. This starts with activation of the immune system in the body in response to such triggers especially in genetically predisposed people. When exposed, the inflammatory mediators including histamines and leukotrienes are released and these result in smooth muscle contractions in the walls of the airways causing the lumen of the airways to reduce. This constriction is further widened by the inflammation of the airway walls, the production of more mucus and swelling that combined hinder movement of air both in and out of the lungs. Consequently, the body cannot effectively exchange carbon dioxide and oxygen, this creates the feeling of shortness of breath and the labored breathing. In asthma, bronchoconstriction is acute and reversible and the application of bronchodilator medications; that is, beta-agonist has proven to be quite effective in relieving the airway constricting caused by an increase in smooth muscle relaxation. It is a mechanism on which rapid-acting or rescue medications in asthma attacks are based. Although bronchoconstriction is usually a reversible change, when untreated or aggravated in the long term, the process may result in more chronic airflow restriction and permanent lung dysfunction. Repeated instances of bronchoconstriction in chronic asthma may also participate in airway remodelling, a process whereby the airways structure alters and as a result, the airways become thickened with more smooth muscle and fibrosis making it harder to reverse bronchoconstriction. This development shows that early diagnosis and proper management is necessary to ensure that the condition does not deteriorate and that long-term lung health is preserved. Bronchoconstriction also plays an essential role in asthma attacks and symptoms become much more serious and need more medical treatment in this case. Such exacerbations may be spontaneous or induced by certain environmental elements like respiratory infection or exposure to allergens. Bronchoconstriction has been observed in other conditions like chronic obstructive pulmonary disease (COPD) and bronchitis, among others, where it has been noted to lead to chronic airflow limitation and respiratory distress. Bronchodilators and anti-inflammatory medications are the major management options of bronchoconstriction availability in children with asthma to control symptomatic and limit the rate of attacks. The long-term management approach aims at prevention and detection of triggers, management of medicines as well as non-pharmacological interventions as breathing exercise to enhance respiratory functions. The knowledge of the mechanisms and triggers of bronchoconstriction is important in enhancing management and coming up with better, more specific treatment that can help in reducing the symptoms, preventing attacks and eventually improving the quality of life of the children affected[17–19].

Pulmonary Function Testing

Pulmonary function testing (PFT) is one of the most important diagnostic tools that can be used to determine the functional status of the lungs, and is needed in the evaluation, diagnosis, and management of many respiratory disease categories, such as asthma, chronic obstructive pulmonary disease (COPD), and interstitial lung disease. Airflow, lung volumes and gas exchange are the main elements of lung functioning which are measured by the tests and can give important information about the lung disease presence and degree. PFTs play an important role in diagnosing asthma in children whose clinical picture is indistinct or when the symptoms are sporadic. The most widespread PFTs are spirometry, lung volume measurement and diffusing capacity tests which assess various parameters of lung function. The most common PFT that is conducted is spirometry which involves the amount of air that an individual can exhale after taking a deep breath in an intense manner[20–22]. It gives such vital measurements like forced vital capacity (FVC) that is the sum of air exhaled and forced expiratory volume in one second (FEV1) that shows the amount of air to be exhaled within first second of forced expiration. The FEV1/FVC ratio is employed in diagnosing the presence of obstruction of airway diseases including asthma and COPD. A

diminishing FEV1/FVC ratio in asthma is an indication of airway obstruction by narrowing of bronchi, inflammation, and mucus. The other significant element of PFT is the lung volumes taken which might aid in assessing the total size and volume of the lungs. To measure total lung capacity (TLC), and residual volume (RV), such techniques as body plethysmography or helium dilution are employed. These measurements are most effective in the diagnosis of restrictive lung diseases or the level of air trapping in the obstructive diseases. Besides spirometry and lung volume tests, another PFT that determines the level of oxygen uptake by the alveoli to the bloodstream is the diffusing capacity of carbon monoxide (DLCO). A lower value of DLCO may suggest issues with alveolar-capillary membrane and it frequently occurs with such conditions as pulmonary fibrosis or emphysema. PFTs also prove useful when it comes to tracking the development of an illness and measuring the success of therapeutic procedures. Frequent spirometry tests may be employed to evaluate the variation in airway operating in asthma and to change the drugs administration and treatment approaches in response to the results. Moreover, the bronchodilator reversibility test may be conducted as a part of PFT to determine the extent to which the airflow increases under the influence of a bronchodilator, which is typical of asthma, airflow obstruction of which is usually reversible. Although PFTs are important in obtaining the necessary information about the lungs, the interpretation of the findings in children may be more complicated by the differences in lung development, age, size, and effort. It might not be easy to get credible results in young children, therefore other forms of testing of airway inflammation and obstruction can be employed including impulse oscillometry or fractional exhaled nitric oxide (FENO) tests. It is within these difficulties that PFT is still a critical instrument in diagnosing and treating respiratory dysfunctions in children. It allows healthcare providers to make effective decisions based on treatment, monitor the changes in lung functioning over time, and enhance the overall management of such conditions as asthma. With the current development in testing techniques and technology, PFTs still continue to develop, with increased precision and non-invasive options available to the pediatric patients, which eventually improves the quality of service given to children with respiratory conditions[23–25].

Table 1: Breathing Exercises for Asthma Management

Exercise	Description	Benefits
Diaphragmatic Breathing	Breathing deeply using the diaphragm to fill the lungs fully	Increases lung capacity, reduces shortness of breath
Pursed-lip Breathing	Inhale through the nose, exhale slowly through pursed lips	Helps keep airways open, reduces breathlessness
Buteyko Breathing	Focuses on slow, controlled breathing through the nose	Reduces hyperventilation, improves oxygen supply

Table 2: Asthma Management Steps and Medications

Step	Medications	Purpose	Action Plan
Step 1	Short-acting beta-agonists (SABAs)	Relieve acute symptoms	Use as needed for symptom relief
Step 2	Low-dose inhaled corticosteroids (ICS)	Control inflammation	Daily use to prevent symptoms
Step 3	ICS + Long-acting beta-agonists (LABAs)	Prevent asthma attacks	Use regularly, monitor symptoms
Step 4	Medium-dose ICS + LABAs	Control moderate asthma	Adjust doses based on symptoms
Step 5	High-dose ICS + LABAs + Biologics	Severe asthma control	Consider biologic therapy for severe cases

Table 3: Common Asthma Triggers in Children

Trigger	Description	Management Strategies
Dust mites	Found in bedding, carpets, and upholstery	Use allergen-proof covers, reduce humidity
Pet dander	Caused by shedding skin cells from animals	Keep pets out of the bedroom, bathe pets frequently
Pollen	Seasonal allergens from trees, grasses, and weeds	Keep windows closed, limit outdoor activity during high pollen counts
Mold	Found in damp areas like bathrooms and basements	Reduce humidity, use dehumidifiers
Tobacco smoke	Irritant that worsens asthma symptoms	Avoid smoking indoors, limit exposure to secondhand smoke

Air pollution	Can worsen asthma symptoms in urban areas	Avoid outdoor exercise during high pollution times

Figure 1: Pathophysiology of Asthma in Children



Figure 2: School and Community-Based Asthma Care

Pharmacological Management

The pharmacological treatment is one of the pillars of the treatment of asthma especially among children because it is used to manage the symptoms, prevent asthma attacks, and enhance the overall lung functioning. The main objective of pharmacological treatment in asthma in children is to obtain and sustain control of asthma that is characterized by the lack of symptoms, the possibility to appropriately perform physical activity, and the low possibility of using rescue medication[26–28]. Management approach is that of combining both reliever (or rescue) drugs and controller (or maintenance) drugs that play a different purpose in the management. Reliever drugs, including short-acting beta-agonists (SABAs) like albuterol, are fast-acting drugs that relax the muscle around the airways reversing bronchoconstriction and airway blockage, which restore airflow. These drugs are normally taken when asthma attacks or during the aggravation of symptoms, and they are immediate and provide temporary relief. Nevertheless, SABAs can be effective as a form of fast-acting methods of symptom relief, but they do not solve the inflammation underlying asthma, and that is why they cannot be used in long-term management. Controller medications are necessary to control asthma on a long-term basis. The long-term management of asthma is anchored on the use of inhaled corticosteroids (ICS) because they have strong anti-inflammatory properties. ICS assist in the prevention of asthma attacks and in the enhancement of the lung functioning. Such medications are normally taken on a

daily basis to keep asthma under control and their prescription may be done in different doses depending on the symptoms of the child. ICS is used together with long-acting beta-agonists (LABAs) when treating moderate or severe asthma. LABAs are also beneficial in longer-lasting bronchodilation and provide symptom protection of up to 12 hours of protection, and are useful especially in preventing nocturnal asthma symptoms and as a whole in asthma management. Nevertheless, LABAs cannot be applied independently in the management of asthma because they do not address the inflammation and may predispose asthma attacks in case it is not complemented with an ICS. Another category of controller drugs that inhibit the production of the leukotrienes, which are inflammatory substances that cause asthma, is referred to as leukotrienes modifiers that include montelukast. These drugs assist in minimizing bronchoconstriction, mucuid and inflammation and they could be taken as supplements to ICS particularly in children who cannot allure inhaled drugs or those with mild asthma. Biologic therapies have also taken up a significant position in more serious forms of asthma. Biologics are used in patients that have severe and uncontrolled asthma (e.g., omalizumab, mepolizumab) as monoclonal antibodies against specific inflammatory mediators (e.g., interleukins). The mechanism of action of these therapies is in regulating the activity of the immune system towards allergens and inflammatory stimuli and are usually only used in children with asthma that is not easily controlled using conventional drugs. Oral treatment should complement the properly used inhaler administration and compliance with the medication schedule as the pharmacological treatment is necessary in asthma treatment. Patient and caregiver education is an important part of asthma treatment, because improper use of an inhaler or poor compliance may result in inadequate control and high rates of exacerbation. Besides drugs, non-pharmacological techniques of management should be noted, including environmental control, prevention of triggers, and frequent monitoring of symptoms of asthma. In general, the pharmacological treatment of the pediatric asthma is a personalized and step-by-step process that must consider the symptoms severity, response rate to treatment and the needs of the child. Most asthmatic children are able to have good control and live an active and healthy life with proper use of medication and constant monitoring[29–31].

Reliever Medications and Controller Medications

Reliever medication, as well as, controller (or maintenance) medication, have a key role in the management of asthma in children to ensure effective symptoms control, exacerbation prevention, and improvement of the overall quality of life. Reliever drugs are meant to relieve the symptoms of the acute form of asthma especially during an asthma attack or when the symptoms are aggravated by exposure to triggers like allergens, respiratory infections, or physical activity. Short-acting beta-agonists (SABAs), including albuterol, are the most commonly used reliever medications and they act by quickly relaxing smooth muscles of the airways, hence overturning bronchoconstriction and enhancing airflow[28,32,33]. These drugs are fast acting and offer good relief of symptoms like wheezing, coughing and breathlessness and this may just take a few minutes after taking the drugs. Nevertheless, SABAs are only effective to a small extent because they fail to deal with the underlying inflammation that results in asthma, and excessive use of such drugs can point to asthma management. Thus, reliever medications are not effective in long-term management and should be utilized together with controller medications, which can help to control the underlying inflammation of asthma. On the contrary, controller medications are administered on a daily basis to decrease airway inflammation, prevent asthma attack, and control asthma long-term. Inhaled corticosteroids (ICS) are the main component of the controller therapy that includes anti-inflammatory drugs that act by preventing exacerbations and improving lung functioning by decreasing swelling and mucus secretion in the airways. ICS are generally administered as different doses every day with the dose depending on the extent of asthma. Inhaled corticosteroids have proven to be very efficacious in minimizing the rate and increasing the magnitude of asthma symptoms, and they are regarded as the first-line medication in the long-term control of asthma symptoms in children. Long-acting beta-agonists (LABAs) might also be used in the addition to ICS therapy among children with medium or severe asthma. LABAs, including salmeterol and formoterol, offer a long-lasting protection of bronchodilation up to 12 hours and help to prevent nocturnal symptoms and enhance asthma control on the whole. Nevertheless, LABAs must never be used as an alternative to ICS, since they do not resolve inflammation by themselves and can predispose the patient to asthma attacks in case of their use. Another type of controller medications is referred to as leukotrienes modifiers like montelukast, which operates by inhibiting leukotrienes, which are inflammatory substances that aid in bronchoconstriction, edema, and mucus secretion in the airways. The leukotrienes modifiers can also be applied as an adjunct to ICS in the cases of mild asthma or to the children who have the problem with using inhalers. Biologic therapies, including monoclonal antibodies against particular inflammatory pathways (e.g., omalizumab, mepolizumab) can be implemented in more severe asthma cases. Biologics are developed with specific aims to target and inhibit certain molecules in the

inflammatory process and provide specific treatment to children with severe and uncontrolled asthma. The treatment is usually applied to children who have asthma and which cannot be controlled by regular medications. Reliever and controller medications play a crucial role in the treatment of pediatric asthma and the desired outcome is to balance between the two and avoid symptoms, reduce attacks, and normalize lung functionality. The method of administration and the management of asthma depends on the inhaler technique and medication adherence, since improper inhalers use or the use of irregular medications may result in poor asthma control and frequent exacerbation. Frequent observation of the symptoms, continuous patient and caregiver education should be a goal in reaching asthma control and control, enabling children to live an active and healthy life[30,31,34].

Stepwise Therapy Approach

The step-wise treatment programme is a systematic programme applied in the management of asthma among children and is aimed at giving an individualized treatment based on the severity and frequency of asthma symptoms. It is a method of raising the degree of medication up or down as the degree of asthma control is reached. The major aim of stepwise therapy is to ensure that the best asthma management is achieved using the minimal dosage of medication as possible hence avoiding side effects and at the same time ensuring that treatment is as effective as possible[26,28,35]. The strategy is split into various stages, and each of the stages is attributed to a particular treatment plan. In the case of intermittent asthma in children with mild symptoms and a frequency of less than two instances per week, the starting point of therapy is the administration of short acting beta-agonist (SABAs) on an as needed basis to relieve symptoms. These drugs are quick bronchodilators assisted to reverse bronchoconstriction during asthma attacks. In case of the continuation or increase in the frequency of the symptoms, step 2, which includes the introduction of inhaled corticosteroid (ICS) in low doses and regular intake, is recommended in the stepwise approach. ICS have become the backbone of long term asthma management since they deal with the underlying airway inflammation that causes asthma symptoms. In children with persistent asthma, with more regular symptoms or ones that disrupt daily life, an increase in doses of ICS can be used, alone or along with long-acting beta-agonist (LABAs) at step 3. LABAs like salmeterol are known to provide long term bronchodilations thus prevent the occurrence of symptoms at night and overall asthma management. In few instances, leukotrienes modifiers, e.g. montelukast can be administered alongside ICS especially in children who have a hard time with the inhalers or those with mild asthma. The 4 th and 5 th steps are to be used with the moderate and severe asthma children with more intensive management. At step 4, ICS of medium dose with LABAs is commonly prescribed, and further drugs like leukotrienes modifiers or theophylline can be used. In step 5, the high-dose ICS and LABAs, as well as biologic treatments, such as omalizumab or mepolizumab, could be used in case of children with severe and uncontrolled asthma. Biologics are specific therapies that target a particular inflammatory pathway in asthma, and are normally administered to children who do not respond to conventional treatment. Treatment is modified during the stepwise approach through frequent (at least once every 8 weeks) evaluations of asthma control, which encompasses measuring the frequency of symptoms, medication use, and lung function. When the management of asthma is improved, the treatment program can be reduced to a lower level to reduce the use of medication and decrease the possibility of side effects. On the other hand, when asthma management becomes worse, the management plan may be escalated to a more vigorous therapy to ensure that exacerbation does not occur and that sufficient symptoms control is maintained. [36–38].

Non-Pharmacological Management

The non-pharmacological management of asthma in children is relevant in the integrated treatment of the illness as a supplement to pharmacological interventions to aid in symptom control, exacerbation optimization, and the general quality of life in children with asthma. These measures are meant to tackle environmental, behavioral and lifestyle determinants which may be triggers or exacerbation of asthma symptoms and is a more holistic approach to asthma care. Allergen and irritant avoidance is one of the main elements of non-pharmacological management that involves the identification and elimination of contact with environmental exposures including dust mites, pet dander, pollen, mold, and tobacco smoke. As an illustration, allergen-proof mattresses, no pets in bedrooms, low humidity at home can contribute greatly to the reduction of asthma flare-ups[39–41]. The quality of air is also a factor, where it has been advised not to be exposed to pollution, second hand smoke and strong odors, which can worsen the asthma symptoms. Breathing exercises are the other main non-pharmacological solution that is used to enhance the lung functionality and to decrease the instances of attacks. Diaphragmatic breathing, pursed-lip breathing, and Buteyko method are some of the techniques that can be used to ensure that children can regulate their breathing patterns, relax respiratory muscles, and increase the airflow to lungs. Such exercises can be especially beneficial at the time of asthma attacks or as a

part of a regular activity to increase the capacity of lungs and decrease hyperventilation. Exercise is also an important component of asthma management, even though at times exercise triggers an asthma attack, moderate exercise taken on a regular basis is good exercise to be done in general regarding the breathing health. Exercising assists in strengthening the respiratory muscles, cardiovascular health and general fitness that can lessen the symptoms of asthma in the long run. Nevertheless, the child should be observed with respect to asthma symptoms and proper warm-up and cool-down exercises to prevent the occurrence of bronchoconstriction, which is caused by exercise as much as possible. Along with these interventions, the child and their family should receive asthma education. The training of caregivers and children on asthma triggers, medication, correct inhaler technique and need to follow an asthma action plan is an important component in achieving asthma management effectiveness. This education will be able to empower families to be quick and responsive in case of an asthma attack to enhance long-term control of asthma. The other significant element of the non-pharmacological management is the consideration of the psychological and emotional health of asthma children. Chronic illnesses such as asthma may cause anxiety, stress and helplessness which may adversely affect the management of asthma. Counseling and support groups are able to assist the children and the families with emotional difficulties of handling a chronic illness, which could decrease the stress that can lead to the occurrence of asthma flare-ups. Lastly, a non-pharmacological intervention that is significant in asthma management is in schools and communities. Schools may contribute positively to the management of asthmatic children by availing their drugs to asthmatic children, providing an asthma-friendly environment, and training teachers and other school personnel on how to identify pronouncers of asthma and to respond to asthma attacks. With the non-pharmacological approaches included in the management plan, asthmatics children will be able to gain a greater control over their disease, have fewer symptoms, and live active and fruitful life[2,42].

CONCLUSION

Pediatric asthma management requires a comprehensive approach combining pharmacological treatment, non-pharmacological strategies, patient education, and community support to achieve optimal symptom control and improved quality of life. Healthcare professionals, especially nurses, play a crucial role in monitoring, education, and ensuring treatment adherence. Despite existing challenges such as poor adherence, environmental triggers, and healthcare disparities, emerging advancements in personalized medicine, biologic therapies, and digital health technologies offer promising improvements. A collaborative, multidisciplinary approach involving families, schools, and communities is essential for effective long-term asthma care in children

REFERENCES

1. Custovic, A., De Moira, A. P., Murray, C. S., & Simpson, A. (2023). Environmental influences on childhood asthma: Allergens. *Pediatric Allergy and Immunology, 34*.
2. Pham, D. L., Le, K.-M., Truong, D. D. K., Le, H. T. T., & Trinh, T. H. K. (2023). Environmental allergen reduction in asthma management: An overview. *Frontiers in Allergy, 4*.
3. Bisoffi, L., Sassudelli, G., Agostinis, F., Cogo, A., Cutrera, R., Dalpiaz, I., et al. (2024). Pediatric asthma and altitude: A complex interplay between different environmental factors. *Italian Journal of Pediatrics, 50*.
4. Xu, H.-Z., Lin, N., Bai, G.-N., Liu, Y.-L., Jia, X.-H., Huang, C., et al. (2026). Comprehensive exercise recommendations for pediatric asthma: An evidence synthesis. *World Journal of Pediatrics, 22*.
5. Kanannejad, Z., Taylor, W. R., Mohkam, M., & Ghatee, M. A. (2025). Urban lifestyle and climate-driven environmental exposures: Immunological consequences for pediatric respiratory allergies. *Immunity, Inflammation and Disease, 13*.
6. Guarnieri, G., Caminati, M., Achille, A., Vaia, R., Chieco Bianchi, F., Senna, G., et al. (2022). Severe asthma, telemedicine, and self-administered therapy: Listening first to the patient. *Journal of Clinical Medicine, 11*, 960.
7. Indolfi, C., Klain, A., Capuano, M. C., Colosimo, S., Rapillo, R., & Miraglia Del Giudice, M. (2025). Severe asthma in school-age children: An updated appraisal on biological options and challenges in this age group. *Children, 12*, 167.
8. Lebold, K. M., Jacoby, D. B., & Drake, M. G. (2020). Inflammatory mechanisms linking maternal and childhood asthma. *Journal of Leukocyte Biology, 108*, 113–121.
9. Liu, C., Makrinioti, H., Saglani, S., Bowman, M., Lin, L.-L., Camargo, C. A., et al. (2022). Microbial dysbiosis and childhood asthma development: Integrated role of the airway and gut microbiome, environmental exposures, and host metabolic and immune response. *Frontiers in Immunology, 13*.
10. Papadopoulos, N. G., Apostolidou, E., Miligkos, M., & Xepapadaki, P. (2024). Bacteria and viruses and their role in the preschool wheeze to asthma transition. *Pediatric Allergy and Immunology, 35*.

11. Yagi, K., Asai, N., Huffnagle, G. B., Lukacs, N. W., & Fonseca, W. (2022). Early-life lung and gut microbiota development and respiratory syncytial virus infection. *Frontiers in Immunology, 13*.
12. Binns, E., Tuckerman, J., Licciardi, P. V., & Wurzel, D. (2022). Respiratory syncytial virus, recurrent wheeze and asthma: A narrative review of pathophysiology, prevention and future directions. *Journal of Paediatrics and Child Health, 58*, 1741–1746.
13. Soni, A., Kabra, S. K., & Lodha, R. (2023). Respiratory syncytial virus infection: An update. *Indian Journal of Pediatrics, 90*, 1245–1253.
14. Wu, A. C., Dahlin, A., & Wang, A. L. (2021). The role of environmental risk factors on the development of childhood allergic rhinitis. *Children, 8*, 708.
15. León, B. (2023). Understanding the development of Th2 cell-driven allergic airway disease in early life. *Frontiers in Allergy, 3*.
16. Pybus, H. J., Dangarh, P., Ng, M. Y. M., Lloyd, C. M., Saglani, S., & Tanaka, R. J. (2025). Mechanistic modelling of allergen-induced airways disease in early life. *Scientific Reports, 15*.
17. Rosenwasser, Y., Berger, I., & Loewy, Z. G. (2022). Therapeutic approaches for chronic obstructive pulmonary disease (COPD) exacerbations. *Pathogens, 11*, 1513.
18. Shibata, Y., Kawayama, T., Muro, S., & Sugiura, H. (2023). Management goals and stable phase management of patients with chronic obstructive pulmonary disease in the Japanese Respiratory Society guideline for the management of chronic obstructive pulmonary disease 2022 (6th edition). *Respiratory Investigation, 61*, 773–780.
19. Foster, K., & Wong, C. Y. J. (2024). Advances in inhaler therapy for asthma and chronic obstructive pulmonary disease: A comprehensive review of FostairTM and TrimbowTM. *Journal of Pharmacy and Pharmacology, 76*, 1301–1309.
20. Jat, K. R., & Agarwal, S. (2023). Lung function tests in infants and children. *Indian Journal of Pediatrics, 90*, 790–797.
21. Bae, J., Lee, H. J., Choi, K. Y., Lee, J.-K., Park, T. Y., Heo, E. Y., et al. (2024). Risk factors of acute exacerbation and disease progression in young patients with COPD. *BMJ Open Respiratory Research, 11*, e001740.
22. Blomberg, A., Torén, K., Liv, P., Granåsen, G., Andersson, A., Behndig, A., et al. (2024). Chronic airflow limitation, emphysema, and impaired diffusing capacity in relation to smoking habits in a Swedish middle-aged population. *Annals of the American Thoracic Society, 21*, 1678–1687.
23. Garg, R., Piplani, M., Upadhayay, A., Singh, Y., & Bhateja, P. (2024). A review on comparison of allopathic medicines to other drug therapies in the management of asthma. *Infectious Disorders - Drug Targets, 24*.
24. Ora, J., Giorgino, F. M., Bettin, F. R., Gabriele, M., & Rogliani, P. (2024). Pulmonary function tests: Easy interpretation in three steps. *Journal of Clinical Medicine, 13*, 3655.
25. Ojha, T., Patel, A., Sivapragasam, K., Sharma, R., Vosoughi, T., Skidmore, B., et al. (2024). Exploring machine learning applications in pediatric asthma management: Scoping review. *JMIR AI, 3*, e57983.
26. Lin, G.-Q., Ye, Z.-Q., Song, E.-L., & Lin, Y.-N. (2024). Enhancing pediatric asthma management through multifaceted health education. *World Journal of Clinical Cases, 12*, 3708–3716.
27. Maglione, M., Borrelli, M., Dorato, A., Cimbalo, C., Del Giudice, L. A., & Santamaria, F. (2024). Mepolizumab in severe pediatric asthma: Certainties and doubts through a single-center experience and review of the literature. *Children, 11*, 895.
28. Di Cicco, M. E., Peroni, D., Marseglia, G. L., & Licari, A. (2025). Unveiling the complexities of pediatric asthma treatment: Evidence, controversies, and emerging approaches. *Pediatric Drugs, 27*, 393–404.
29. Akca Sumengen, A., Simsek, E., Ozcevik Subasi, D., Cakir, G. N., Semerci, R., & Gregory, K. L. (2024). Pediatric asthma inhaler technique: Quality and content analysis of YouTube videos. *Journal of Asthma, 62*, 24–35.
30. Adisa, R., Ufuah, U. F., & Ige, O. M. (2024). Impact of pharmacist-led intervention in medication adherence and inhaler usage on asthma and chronic obstructive pulmonary disease control: A quasi-experimental study. *BMC Health Services Research, 24*.
31. Poplicean, E., Crișan, A. F., Tudorache, E., Hogea, P., Mladin, R., & Oancea, C. (2024). Unlocking better asthma control: A narrative review of adherence to asthma therapy and innovative monitoring solutions. *Journal of Clinical Medicine, 13*, 6699.
32. Mosnaim, G. S., Hoyte, F. C. L., Safioti, G., Brown, R., Hill, T. D., Li, T., et al. (2023). Effectiveness of a maintenance and reliever Digihaler system in asthma: 24-week randomized study (CONNECT2). *Journal of Allergy and Clinical Immunology: In Practice, 12*, 385–395.e4.
33. Barry, T., Holliday, M., Sparks, J., Biggs, R., Colman, A., Lamb, R., et al. (2024). START CARE: A protocol for a randomised controlled trial of step-wise budesonide-formoterol reliever-based treatment in children. *ERJ Open Research, 10*, 00897–2023.

34. Mosnaim, G., Carrasquel, M., Ewing, T., Berty, A., & Snedden, M. (2025). Remote monitoring in asthma: A systematic review. *European Respiratory Review, 34*, 240143.
35. Lovrić, M., Banić, I., Lacić, E., Pavlović, K., Kern, R., & Turkalj, M. (2021). Predicting treatment outcomes using explainable machine learning in children with asthma. *Children, 8*, 376.
36. Fildan, A. P., Rajnoveanu, R.-M., Cirjaliu, R., Pohrib, I., Tudorache, E., Ilie, A. C., et al. (2021). Biological therapies targeting the type 2 inflammatory pathway in severe asthma (Review). *Experimental and Therapeutic Medicine, 22*.
37. Cheng, Z. R., Tan, Y. H., Teoh, O. H., & Lee, J. H. (2021). Keeping pace with adolescent asthma: A practical approach to optimizing care. *Pulmonary Therapy, 8*, 123–137.
38. Chang, A. B., Bell, S. C., Byrnes, C. A., Dawkins, P., Holland, A. E., Kennedy, E., et al. (2023). Thoracic Society of Australia and New Zealand (TSANZ) position statement on chronic suppurative lung disease and bronchiectasis in children, adolescents and adults in Australia and New Zealand. *Respirology, 28*, 339–349.
39. O'Keefe, A., Connors, L., Ling, L., & Kim, H. (2025). Asthma. *Allergy, Asthma & Clinical Immunology, 20*.
40. Liu, N. M., Pijnenburg, M. W., Deschildre, A., De Mir-Messa, I., Adalen, S., Amat, F., et al. (2025). Severe paediatric asthma collaborative in Europe: Real-world data on children on biologics. *ERJ Open Research, 11*, 00709–2024.
41. Indolfi, C., Klain, A., Miraglia Del Giudice, M., De Filippo, M., Marseglia, A., Marseglia, G. L., et al. (2025). The use of biologic therapies in pediatric severe asthma. *Expert Review of Respiratory Medicine, 19*, 1209–1219.
42. Van Dijk, Y. E., Brandsen, M. A., Hashimoto, S., Rutjes, N. W., Golebski, K., Vermeulen, F., et al. (2024). Factors influencing the initiation of biologic therapy in children with severe asthma: Results of the pediatric asthma noninvasive diagnostic approaches (PANDA) study. *Pediatric Pulmonology, 59*, 2875–2884.